Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neostigmine/glycopyrrolate vs sugammadex for neuromuscular blockade reversal in elderly patients
2023-504230-21-00Phase 4Completed
- Sponsor
- Rigshospitalet
- Start
- Jun 2023
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in neuromuscular block (NMB) comparing Neostigmine/glycopyrrolate with Sugammadex (2 arms). Primary endpoint: Time to TOF > 0.9. Started Jun 2023; status: completed.
02
Drugs
Sugammadexneostigmine + glycopyrrolate
03
Conditions
neuromuscular block (NMB)
Beyond the preview
Go deeper on 2023-504230-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504230-21-00.